Hogan Lovells Publications

UK M&A: Brexit and investment in UK life sciences

While Brexit is likely to result in sweeping changes to the UK’s life sciences sector, the rate of M&A and foreign investment is a positive sign that the region will uphold its...

Hogan Lovells Publications

Braced for Brexit

As negotiations continue, so do business preparations. Change is almost inevitable but the extent, nature and timing is uncertain. How can such change be addressed in one-off transactions...

Hogan Lovells Publications

What does Brexit mean for life sciences companies in the EU and UK?

June 2016’s historic Brexit vote has created confusion and uncertainty in both the UK and the EU, with businesses struggling to understand the long-term impacts. Elisabethann Wright,...

Hogan Lovells Publications

Lower regulatory barriers may accelerate innovation for drug and device manufacturers

While the FDA has in recent years relaxed regulations in certain areas — such as generic drug approval — advances like innovative new combination products (the use of a device...

Loading data